Development and validation of a high‐performance liquid chromatography method for the quantification of talazoparib in rat plasma: Application to plasma protein binding studies. (15th August 2017)

• Record Type: Journal Article
• Authors: Hidau, Mahendra Kumar; Kolluru, Srikanth; Palakurthi, Srinath
• Is Part Of: Biomedical chromatography. Volume 32:Number 2(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-08-15
• Subjects: chromatography -- PARP inhibitor -- protein binding; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.4046
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: A sensitive and selective RP‐HPLC method has been developed and validated for the quantification of a highly potentpoly ADP ribose polymerase inhibitor talazoparib (TZP) in rat plasma. Chromatographic separation was performed with isocratic elution method. Absorbance for TZP was measured with a UV detector (SPD‐20A UV–vis) at a λ max of 227 nm. Protein precipitation was used to extract the drug from plasma samples using methanol–acetonitrile (65:35) as the precipitating solvent. The method proved to be sensitive and reproducible over a 100–2000 ng/mL linearity range with a lower limit of quantification (LLQC) of 100 ng/mL. TZP recovery was found to be >85%. Following analytical method development and validation, it was successfully employed to determine the plasma protein binding of TZP. TZP has a high level of protein binding in rat plasma (95.76 ± 0.38%) as determined by dialysis method.